RxDoctor Payments Data

Abelardo Martinez-Rumayor, MD

Interventional Cardiology · San Antonio, TXNPI 1861528234

Payments from drug & device makers

$64,008in general payments, 2019–2025

Across 203 payments — averaging $315.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$58K
  • Abiomed$2K
  • Novartis$998
  • Medtronic$734
  • Johnson & Johnson$478
  • Boston Scientific$467
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$6,60047%
  • Travel & lodging$1,66012%
  • Food & beverage$5,56840%
  • Education$1451%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,008 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$185,597
Medicare patients
661
Services billed
1,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$186,970
EntrestoSacubitril/Valsartan78$96,055
JardianceEmpagliflozin47$57,316
XareltoRivaroxaban57$49,937
BrilintaTicagrelor33$29,863
Repatha SyringeEvolocumab27$25,449
FarxigaDapagliflozin Propanediol19$21,094
VascepaIcosapent Ethyl17$13,548
Praluent PenAlirocumab14$12,669
Repatha SureclickEvolocumab18$9,402
Diltiazem 12hr ErDiltiazem Hcl32$4,164
Metoprolol Succinate335$3,869
Atorvastatin Calcium380$3,685
Rosuvastatin Calcium334$3,471
Losartan Potassium292$2,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$145$186,970176 claims
NovartisEntresto$998$96,05578 claims
Boehringer IngelheimJardiance$29$57,31647 claims
AstraZenecaBrilinta, Farxiga$50$50,95752 claims
Johnson & JohnsonXarelto$478$49,93757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →